| Trial | Treatments | Patients | Method |
|---|
| NSABP B31, 2005 | 52 weeks of trastuzumab (n=-9) vs. no trastuzumab (n=-9) | patients with node-positive, HER2-positive breast cancer | Parallel groups Sample size: -9/-9 Primary endpoint: FU duration: |
| BCIRG006, 2013 | (n=-9) vs. (n=-9) | | Sample size: -9/-9 Primary endpoint: FU duration: |
| Buzdar, 2005 | simultaneous weekly trastuzumab for 24 weeks (n=-9) vs. no trastuzumab (n=-9) | patienst with HER 2-positive operable breast cancer | Parallel groups Sample size: -9/-9 Primary endpoint: FU duration: |
| FinHer, 2006 | concomitant treatment with trastuzumab (n=-9) vs. no trastuzumab (n=-9) | Women with tumors that overexpressed HER2/neu | Parallel groups Sample size: -9/-9 Primary endpoint: FU duration: |
| HERA, 2005 | ??? (n=-9) vs. ??? (n=-9) | patients with HER2-positive and either node-negative or node-positive breast cancer who had completed locoregional therapy and at least four cycles of neoadjuvant or adjuvant chemotherapy | Sample size: -9/-9 Primary endpoint: FU duration: |
| N9831, 2005 | (n=-9) vs. (n=-9) | | Sample size: -9/-9 Primary endpoint: FU duration: |
| NOAH, 2010 | 1 year of treatment with trastuzumab (given as neoadjuvant and adjuvant treatment (n=-9) vs. no trastuzumab (n=-9) | patients with HER2-positive locally advanced breast cancer | Sample size: -9/-9 Primary endpoint: FU duration: |
| PACS-04, 2009 | (n=-9) vs. (n=-9) | | Sample size: -9/-9 Primary endpoint: FU duration: |
| N9831 (1) | (n=-9) vs. (n=-9) | | Sample size: -9/-9 Primary endpoint: FU duration: |
| N9831 (2) | (n=-9) vs. (n=-9) | | Sample size: -9/-9 Primary endpoint: FU duration: |
| FinHer (1) | (n=-9) vs. (n=-9) | | Sample size: -9/-9 Primary endpoint: FU duration: |
